Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities:
Net loss	$ (25,939)	$ (22,639)
Items not involving cash:
Depreciation	445	502
Amortization of discount on term loan	156
Stock-based compensation	2,050	1,643
Unrealized foreign exchange (gain) loss	269	(1,585)
Gain on termination of collaboration agreement (note 9c)	(4,398)
Changes in operating assets and liabilities:
Accounts receivable	255	77
Prepaid expenses, and other current assets	(1,469)	243
Prepaid expenses, long term	230	190
Accounts payable and accrued expenses	919	(319)
Net cash used in operating activities	(27,482)	(21,888)
Investing activities:
Purchases of property, plant and equipment	(337)	(252)
Purchase of marketable securities	(50,130)	(22,281)
Proceeds from marketable securities	34,036	41,024
Net cash provided by (used in) investing activities	(16,431)	18,491
Financing activities:
Proceeds from issuance of refinanced term loan, net of issuance costs (note 8)	8,453
Issuance of common shares, net of issuance costs (note 9a)	102,842
Issuance of common shares pursuant to exercise of stock options	262	177
Net cash provided by financing activities	111,557	177
Effect of exchange rate changes on cash and cash equivalents	(168)	813
Increase (decrease) in cash and cash equivalents	67,476	(2,407)
Cash and cash equivalents, beginning of period	20,486	17,095
Cash and cash equivalents, end of period	87,962	14,688
Supplemental disclosures:
Interest paid	338
Interest received	518	544
Supplemental disclosures of non-cash transactions:
Fair value of stock options and warrants exercised on a cashless basis	1,112	$ 25
Issuance of preferred shares in exchange for common shares (note 9b)	21,825
Conversion of preferred shares to common shares (note 9b)	9,893
Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]
Supplemental disclosures of non-cash transactions:
Termination of Teva agreement through cancellation of common shares (note 9c)	$ 4,470